Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00336713 · ClinicalTrials.gov registry record · Phase 3
A 24-52-week Study to Evaluate the Long-term Efficacy and Safety of Saredutant in Patients With Depression (MAGENTA)
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 430
- Enrollment target
NCT00336713 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 430 participants.
The verdict
NCT00336713, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 430 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the long-term efficacy and safety of Saredutant in patients with depression. The primary objective is to evaluate the efficacy and safety of Saredutant 100 mg once daily compared to placebo in the prevention of relapse of depressive symptoms in outpatients with major depressive disorder who achieved an initial response to 12 weeks of open-label treatment with Saredutant.
Interventions
- DRUG Placebo
- DRUG Saredutant (SR48968C)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 430 participants |
| Start Date | 2006-05 |
| Est. Completion | 2008-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00336713
The ClinicalTrials.gov registry entry for NCT00336713 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 430 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00336713 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00336713 about?
NCT00336713 is a clinical study titled "A 24-52-week Study to Evaluate the Long-term Efficacy and Safety of Saredutant in Patients With Depression (MAGENTA)". The purpose of the study is to evaluate the long-term efficacy and safety of Saredutant in patients with depression. The primary objective is to evaluate the efficacy and safety of Saredutant 100 mg once daily compared to placebo in the prevention of relapse of depressive symptoms in outpatients wit...
What is the current status of trial NCT00336713?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 430 participants. The study started on 2006-05. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00336713?
The interventions under investigation include: Placebo (DRUG), Saredutant (SR48968C) (DRUG).
Who is sponsoring clinical trial NCT00336713?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.